Research team finds new dual benefit mode of action for a drug candidate to fight COVID-19

A research team led by Prof. Stephan Ludwig, a virologist at the Institute of Virology at the University of Münster, has found a new dual attack mode of action while working on the development of a drug candidate against SARS-CoV-2 infections. This could constitute the basis for a broadly effective drug to fight COVID-19. The data, which have now been published in the journal Cellular and Molecular Life Sciences, provided the basis for the approval issued by the German Institute of Drugs and Medicinal Products for a clinical study currently being worked on.

This article was originally published on

Read More: